**Supplemental Table 2. Overview of Relapse Studies with Approved Antidepressantsa**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Antidepressant** | **Citation** | **Study Design** | **Definition of Relapse** | **Placebo Relapse Rates** | **Antidepressant Relapse Rates** |
| Venlafaxine  75-225 mg/d | (Simon *et al.*, 2004) | 8-week lead-in, followed by 6-months double-blind, placebo-controlled treatment | Reappearance of MDD (DSM-IV criteria) and CGI‑S score ≥4; two consecutive CGI-S scores ≥4; or a final CGI-S score ≥4 for any patient who withdrew from the study for any reason. | 52%b | 28%b |
| Escitalopram  10-20 mg/d | (Rapaport *et al.*, 2004) | 8-week open-label, followed by 36-weeks double-blind, placebo-controlled treatment | MADRS score ≥22 or discontinuation due to an insufficient therapeutic response, as determined by the Investigator. | 40% | 26% |
| Duloxetine  60 mg/d | (Perahia *et al.*, 2006) | 12-week open-label, followed by 26-weeks double-blind, placebo-controlled treatment | CGI–S score increased by ≥2 points compared with week 12, as well as meeting the MINI depression module criteria for MDD at two consecutive visits at least 2 weeks apart. | 43.1%c | 21.9%c |
| Desvenlafaxine  200-400 mg/d | (Rickels *et al.*, 2010) | 12-week open-label, followed by 6-months double-blind, placebo-controlled treatment | HAM-D17 total score ≥16 or CGI-I score ≥6 at any visit; withdrawal from the study because of an unsatisfactory response to treatment as determined by the investigator. | 42% | 24% |
| Vortioxetine  5-10 mg/d | (Boulenger *et al.*, 2012) | 12-week open-label, followed by 24-weeks double-blind, placebo-controlled treatment | MADRS Total Score ≥22 with in first 24 weeks of double-blind period; an unsatisfactory treatment effect (lack of efficacy) as judged by the Investigator. | 26% | 13% |
| Desvenlafaxine  50 mg/d | (Rosenthal *et al.*, 2013) | 20-week open-label, followed by 6-months double-blind, placebo-control treatment | HDRS17 total score ≥16; discontinuation for unsatisfactory response; or hospitalization for depression, suicide attempt, or suicide. | 30.2% | 14.3% |
| a Table includes positive relapse-prevention studies published since the year 2000 that evaluated SNRIs or SSRIs in adults with MDD.  b At 6-months in the double-blind phase; study also reported relapse rates at 3-months.  c Determined using protocol-defined criteria and investigator assessment of patients; this manuscript also reported relapse rates using protocol-defined criteria only. CGI-I, Clinical Global Impression of Improvement; CGI-S, Clinical Global Impression of Severity; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; HAM-D17/HDRS17, Hamilton Rating Scale for Depression – 17-item; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. | | | | | |

**REFERENCES**

Boulenger JP, Loft H, Florea I (2012). A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. *J Psychopharmacol* **26**:1408-1416.

Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, Montgomery SA, Montejo AL, Detke MJ (2006). Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. *Br J Psychiatry* **188**:346-353.

Rapaport MH, Bose A, Zheng H (2004). Escitalopram continuation treatment prevents relapse of depressive episodes. *J Clin Psychiatry* **65**:44-49.

Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C (2010). Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. *J Clin Psychopharmacol* **30**:18-24.

Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA (2013). Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial. *J Clin Psychiatry* **74**:158-166.

Simon JS, Aguiar LM, Kunz NR, Lei D (2004). Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. *J Psychiatr Res* **38**:249-257.